pan pi3k mtor inhibitor sf1126

Drug Overview

SF1126 is an experimental cancer medicine. It belongs to an advanced group of treatments known as Targeted Therapy or “Smart Drugs.” Unlike traditional chemotherapy that attacks all fast-growing cells in the body, this medicine is designed to seek out and block specific signals that cancer cells use to grow, survive, and build their own blood supply. Because it is still being studied in clinical trials, it is not yet available at standard pharmacies or hospitals outside of research settings.

• Generic Name: SF1126 (Investigational agent)
• US Brand Names: None (Experimental drug)
• Drug Class: Pan-PI3K/mTOR Inhibitor (Targeted Therapy)
• Route of Administration: Intravenous (IV) Infusion (Given through a vein)
• FDA Approval Status: Not FDA Approved (Currently strictly limited to clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

SF1126 is considered a “Smart Drug” because of its highly specific mechanism of action. To understand how it works at the molecular level, it is helpful to think of a cancer cell as a runaway car.

Inside human cells, there are communication pathways called PI3K and mTOR. You can think of these pathways as the “gas pedal” for the cell. When the pedal is pressed, it tells the cell to grow, divide, and stay alive. In many cancers, this gas pedal is stuck permanently “on.”

Here is how SF1126 works to fix this problem:

• The Delivery System: SF1126 is designed with a special “homing device” (an integrin-binding peptide). This helps the drug find and attach to specific proteins (called alpha-v beta-3 integrins) that are found mostly on the surface of tumor cells and the new blood vessels feeding the tumor.
• The Dual Blockade: Once it reaches the tumor, the drug breaks down into its active form. It then acts as a “pan-inhibitor,” meaning it blocks all parts of the PI3K pathway. At the same time, it also blocks the mTOR pathway.
• The Result: By blocking both the PI3K and mTOR “gas pedals,” the cancer cell loses its signal to grow. Furthermore, because it attacks the tumor’s blood vessels, the drug essentially starves the cancer of the oxygen and nutrients it needs to survive. Without these signals and nutrients, the cancer cells stop dividing and safely die off.

FDA-Approved Clinical Indications

Because SF1126 is an experimental research drug, it has not received full approval from the United States Food and Drug Administration (FDA) for general public use.

Oncological Uses (Investigational Only):

• Advanced solid tumors (such as kidney, colon, and prostate cancers)
• B-cell malignancies (types of blood cancer)
• Advanced hepatocellular carcinoma (liver cancer)
• Glioblastoma (a type of brain cancer)

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

Because SF1126 is still actively in clinical trials, the exact dosing can change based on the specific study rules and the patient’s cancer type. The information below is based on general Phase I and Phase II clinical trial guidelines.

Note: Individual dosing depends entirely on the clinical trial’s rules and how well the patient’s body handles the medicine.

Clinical Efficacy and Research Results

Recent clinical research (spanning data from early studies through 2024 reviews of PI3K inhibitors) shows how SF1126 performs in human patients. Because it is a targeted therapy in early-phase testing, the main goal of these studies is to prove the drug is safe, rather than looking at long-term 5-year survival rates.

• Tumor Control: In Phase I studies focusing on advanced solid tumors and B-cell cancers, SF1126 successfully showed anti-tumor activity. While the drug did not completely erase tumors in most patients, it achieved “stable disease” in a notable percentage of participants. This means the cancer stopped growing and spreading for a period of time.
• Target Success: Blood tests from patients showed that the drug effectively turned off the PI3K and mTOR signals inside the body, proving that the drug hits its intended molecular targets.
• Current Focus: Researchers are now focusing on combining SF1126 with other treatments. Studies suggest that using this drug alongside standard chemotherapy or other targeted drugs might prevent cancer from building resistance to the treatment.

Safety Profile and Side Effects

Because SF1126 blocks pathways that are also used by healthy cells (especially for managing blood sugar and digestion), it can cause noticeable side effects.

Black Box Warning:

There is currently no FDA “Black Box Warning” because the drug is experimental and unapproved.

Common Side Effects (Occurs in >10% of patients)

• High blood sugar (Hyperglycemia) – This is the most common side effect of PI3K inhibitors.
• Upset stomach and vomiting (Nausea)
• Loose stools (Diarrhea)
• Feeling very tired or weak (Fatigue)
• Skin rashes

Serious Adverse Events

• Severe Hyperglycemia: Blood sugar can rise to dangerous levels, temporarily causing a diabetes-like state.
• Liver Stress: The drug can irritate the liver, causing a spike in liver enzymes (ALT and AST).
• Allergic Reactions: Because it is given through an IV, some patients may have an allergic reaction during the infusion.

Management Strategies

• For High Blood Sugar: Doctors will check blood sugar levels before every dose. If levels go too high, the patient may need to take diabetes pills (like Metformin) or insulin while on the trial.
• For Diarrhea and Nausea: The care team will provide prescription medicines to calm the stomach and stop diarrhea. Drinking plenty of water is essential.
• For Infusion Reactions: The nursing staff will watch the patient closely during the 90-minute IV drip. If a reaction occurs, they will slow down or stop the drip and give allergy medicines.

Research Areas

While there is no direct connection to mainstream stem cell therapies yet, SF1126 is an important part of research into the “tumor microenvironment”—the area around the tumor that helps it grow. By stopping new blood vessels from forming (anti-angiogenesis), SF1126 changes how the tumor interacts with the body. Scientists are currently exploring how Targeted Therapies like SF1126 might be combined with modern immunotherapy. The hope is that by weakening the tumor’s structure and cutting off its food supply, the body’s own immune system will have an easier time stepping in to destroy the remaining cancer cells.

Patient Management and Practical Recommendations

Patient safety is the top priority in any clinical trial. Healthcare teams use strict guidelines to keep patients safe while receiving SF1126.

Pre-treatment Tests to be Performed

• Metabolic Panel: A thorough check of fasting blood sugar (glucose) and HbA1c to make sure the patient does not have uncontrolled diabetes.
• Liver and Kidney Tests: Blood work to ensure the body’s filters are strong enough to process the IV medicine.
• Heart Check: An ECG (electrocardiogram) to ensure a healthy heart rhythm.

Precautions During Treatment

• Patients will need frequent blood tests (sometimes weekly) to monitor blood sugar and liver health.
• Since the medicine can cause tiredness and stomach issues, patients should have a caregiver drive them to and from their IV infusion appointments.

“Do’s and Don’ts” List

• DO check your blood sugar at home if your study doctor asks you to, and keep a daily log.
• DO tell your doctor immediately if you feel extremely thirsty, need to pee very often, or have blurry vision (these are signs of high blood sugar).
• DO eat a balanced, low-sugar diet to help your body manage your glucose levels during the trial.
• DON’T skip your IV infusion appointments, as the medicine needs to be given on a strict schedule to work properly.
• DON’T start any new vitamins, herbal supplements, or over-the-counter medicines without asking your trial doctor first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. SF1126 is an investigational drug and is not approved by the FDA or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available treatment options.